Literature DB >> 27646713

Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring.

Petra Darebna1, Petr Novak2, Radek Kucera3, Ondrej Topolcan3, Miloslav Sanda4, Radoslav Goldman4, Petr Pompach5.   

Abstract

Alternations in the glycosylation of proteins have been described in connection with several cancers, including hepatocellular carcinoma (HCC) and colorectal cancer. Analytical tools, which use combination of liquid chromatography and mass spectrometry, allow precise and sensitive description of these changes. In this study, we use MRM and FT-ICR operating in full-MS scan, to determine ratios of intensities of specific glycopeptides in HCC, colorectal cancer, and liver metastasis of colorectal cancer. Haptoglobin, hemopexin and complement factor H were detected after albumin depletion and the N-linked glycopeptides with fucosylated glycans were compared with their non-fucosylated forms. In addition, sialylated forms of an O-linked glycopeptide of hemopexin were quantified in the same samples. We observe significant increase in fucosylation of all three proteins and increase in bi-sialylated O-glycopeptide of hemopexin in HCC of hepatitis C viral (HCV) etiology by both LC-MS methods. The results of the MRM and full-MS scan FT-ICR analyses provide comparable quantitative readouts in spite of chromatographic, mass spectrometric and data analysis differences. Our results suggest that both workflows allow adequate relative quantification of glycopeptides and suggest that HCC of HCV etiology differs in glycosylation from colorectal cancer and liver metastasis of colorectal cancer. SIGNIFICANCE: The article compares N- and O-glycosylation of several serum proteins in different diseases by a fast and easy sample preparation procedure in combination with high resolution Fourier transform ion cyclotron resonance mass spectrometry. The results show successful glycopeptides relative quantification in a complex peptide mixture by the high resolution instrument and the detection of glycan differences between the different types of cancer diseases. The presented method is comparable to conventional targeted MRM approach but allows additional curation of the data.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FT-ICR; Glycomics; Haptoglobin; Hemopexin; Hepatocellular carcinoma; MRM; Mass spectrometry; N-glycopeptides; O-glycopeptides; Quantification

Mesh:

Substances:

Year:  2016        PMID: 27646713      PMCID: PMC5803557          DOI: 10.1016/j.jprot.2016.09.004

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  62 in total

Review 1.  Alteration of protein glycosylation in liver diseases.

Authors:  Bram Blomme; Christophe Van Steenkiste; Nico Callewaert; Hans Van Vlierberghe
Journal:  J Hepatol       Date:  2008-12-27       Impact factor: 25.083

2.  Top-down analysis of highly post-translationally modified peptides by Fourier transform ion cyclotron resonance mass spectrometry.

Authors:  Andres Guerrero; Larry Lerno; Daniela Barile; Carlito B Lebrilla
Journal:  J Am Soc Mass Spectrom       Date:  2014-11-18       Impact factor: 3.109

3.  A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophoresis.

Authors:  Qin Fu; Christopher P Garnham; Steven T Elliott; Diane E Bovenkamp; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2005-07       Impact factor: 3.984

4.  Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions.

Authors:  K Taketa; C Sekiya; M Namiki; K Akamatsu; Y Ohta; Y Endo; K Kosaka
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

Review 5.  N-linked protein glycosylation in the ER.

Authors:  Markus Aebi
Journal:  Biochim Biophys Acta       Date:  2013-04-10

6.  Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking.

Authors:  Steven R Barthel; Georg K Wiese; Jaehyung Cho; Matthew J Opperman; Danielle L Hays; Javed Siddiqui; Kenneth J Pienta; Bruce Furie; Charles J Dimitroff
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-04       Impact factor: 11.205

7.  Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.

Authors:  Mengjun Wang; Ronald E Long; Mary Ann Comunale; Omer Junaidi; Jorge Marrero; Adrian M Di Bisceglie; Timothy M Block; Anand S Mehta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

8.  Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers.

Authors:  Miyako Nakano; Tsutomu Nakagawa; Toshifumi Ito; Takatoshi Kitada; Taizo Hijioka; Akinori Kasahara; Michiko Tajiri; Yoshinao Wada; Naoyuki Taniguchi; Eiji Miyoshi
Journal:  Int J Cancer       Date:  2008-05-15       Impact factor: 7.396

9.  Mass + retention time = structure: a strategy for the analysis of N-glycans by carbon LC-ESI-MS and its application to fibrin N-glycans.

Authors:  Martin Pabst; Jayakumar Singh Bondili; Johannes Stadlmann; Lukas Mach; Friedrich Altmann
Journal:  Anal Chem       Date:  2007-06-01       Impact factor: 6.986

10.  GlycoSpectrumScan: fishing glycopeptides from MS spectra of protease digests of human colostrum sIgA.

Authors:  Nandan Deshpande; Pia H Jensen; Nicolle H Packer; Daniel Kolarich
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

View more
  14 in total

Review 1.  Recent Advances in the Mass Spectrometry Methods for Glycomics and Cancer.

Authors:  Muchena J Kailemia; Gege Xu; Maurice Wong; Qiongyu Li; Elisha Goonatilleke; Frank Leon; Carlito B Lebrilla
Journal:  Anal Chem       Date:  2017-10-31       Impact factor: 6.986

2.  Quantitative Analysis of Sex-Hormone-Binding Globulin Glycosylation in Liver Diseases by Liquid Chromatography-Mass Spectrometry Parallel Reaction Monitoring.

Authors:  Wei Yuan; Julius Benicky; Renhuizi Wei; Radoslav Goldman; Miloslav Sanda
Journal:  J Proteome Res       Date:  2018-07-16       Impact factor: 4.466

3.  Highly Sensitive O-Glycan Profiling for Human Serum Proteins Reveals Gender-Dependent Changes in Colorectal Cancer Patients.

Authors:  Solomon T Gizaw; Stefan Gaunitz; Milos V Novotny
Journal:  Anal Chem       Date:  2019-04-24       Impact factor: 6.986

Review 4.  Methods for quantification of glycopeptides by liquid separation and mass spectrometry.

Authors:  Haidi Yin; Jianhui Zhu
Journal:  Mass Spectrom Rev       Date:  2022-01-31       Impact factor: 9.011

Review 5.  Mass Spectrometry Approaches to Glycomic and Glycoproteomic Analyses.

Authors:  L Renee Ruhaak; Gege Xu; Qiongyu Li; Elisha Goonatilleke; Carlito B Lebrilla
Journal:  Chem Rev       Date:  2018-03-19       Impact factor: 60.622

Review 6.  A Perspective on the Confident Comparison of Glycoprotein Site-Specific Glycosylation in Sample Cohorts.

Authors:  Joshua A Klein; Joseph Zaia
Journal:  Biochemistry       Date:  2019-12-31       Impact factor: 3.162

7.  Comparison of Different HILIC Stationary Phases in the Separation of Hemopexin and Immunoglobulin G Glycopeptides and Their Isomers.

Authors:  Katarina Molnarova; Petr Kozlík
Journal:  Molecules       Date:  2020-10-13       Impact factor: 4.411

8.  Biomarkers for the Early Detection of Hepatocellular Carcinoma.

Authors:  Neehar D Parikh; Anand S Mehta; Amit G Singal; Timothy Block; Jorge A Marrero; Anna S Lok
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-01       Impact factor: 4.254

Review 9.  Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma.

Authors:  Raphaela Menezes de Oliveira; Carlos Andre Ornelas Ricart; Aline Maria Araujo Martins
Journal:  Front Oncol       Date:  2018-01-15       Impact factor: 6.244

Review 10.  Calculating Glycoprotein Similarities From Mass Spectrometric Data.

Authors:  William E Hackett; Joseph Zaia
Journal:  Mol Cell Proteomics       Date:  2021-01-06       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.